Drug-metabolizing enzymes found primarily in the liver (CYP450) are a major determinant of therapeutic drug response. Polymorphism dependent upon race\ethnic origin for CYP2D6 is now well-established. Despite consistent reports of ethnic differences in pharmacologic response to antidepressants and neuroleptics, there is a paucity of data on controlled clinical trials and studies determining polymorphic characteristics of CYP2D6 enzymes in African-Americans. There is little and conflicting information available on black populations (Africans, bushmen, Australian Aborigines or African Americans). The prevalence of poor metabolizers in Black populations has been estimated from 0 to 19 %, compared with consistent reports of poor metabolizer status in Caucasians (5-10 %) and Asians (0-2 %). Within the extensive metabolizer category, Asians have higher metabolic ratios (that is, slower metabolism) than Caucasian extensive metabolizers. A high frequency of a mutant gene, CYP2D6*10 has been associated with the slower metabolic rate in Asians. Previous research suggests that slower metabolic rates compared with Caucasians may also be characteristic of Black populations. Recent reports suggest that a novel gene mutant in Black populations, CYP2D6*17, associated with a slower metabolic rate, may occur in a high frequency in these populations. Common clinical practice, supported by controlled clinical studies in Asians, have led to a reduction in dosage recommendations for many antidepressants and neuroleptics for this ethnic group. It is imperative that the determinants of bioavailability be established in African-Americans in order to establish rational drug therapy guidelines for this population.
ted the interest and importance of these pharmacogenetic factors in determining drug responses. Phenotyping of populations has utilized probe drugs as substrates for a particular CYP450 family or investigated patients taking drugs chronically for therapeutic reasons and analysed steady-state levels. In a typical phenotyping study, the probe drug is given, then biological samples are collected over a period of time. Subsequently, the parent compound\metabolite ratio (metabolic ratio, MR) is used to determine metabolic status. Participants who metabolize the parent compound rapidly will have more of the metabolite than the parent compound present in the urine after a predetermined time, resulting in a small MR. Conversely, those who metabolize more slowly will have a larger proportion of the parent compound relative to the metabolite, resulting in higher MRs. Probe drugs metabolized by CYP2D6 produce MRs that are bimodally distributed into extensive metabolizers (EM) and poor metabolizers (PM) , that are clearly separated and identified by an antimode. It is not uncommon in PMs for the metabolite to be below detectable limits some hours after administration of the probe drug. Although CYP2D6 represents only about 1.5 % of the total liver enzymes : for example, compared with CYP3A4, which represents 28 % (Shimada et al., 1994) , the metabolism of a number of important drugs is mediated by CYP2D6 (Table 1) . Plasma levels of other drugs mediated by CYP2D6 have been shown to be increased in PMs of CYP2D6 probe drugs (von Bahr et al., 1991 ; Dahl et al., 1991 ; Eichelbaum and Gross, 1992 ; Hamelin et al., 1996 ; Llerena et al., 1992 ; Meyer et al., 1990) .
Genetic diversity of CYP2D6
From wide-ranging studies, it appears that the incidence of PM is similar among Caucasians (5-10 %), regardless of the country or continent they inhabit (Alva! n et al., 1990) . However, Asians (Chinese, Japanese, Koreans, and broadly including Indian populations) have a much lower incidence of PM, usually 0-2 % (see Table 2 ). The most commonly-studied population group in controlled clinical pharmacology studies has been Asian, perhaps because Asians represent more than half the world's population (Silver et al., 1993) . Africans and those of African descent (for example African Americans) have been infrequently studied, in spite of the fact that the data available indicate that there may be significant racial differences in CYP2D6-mediated metabolism (Edeki, 1996 ; Kalow, 1991 ; Silver et al., 1993 ; Strickland et al., 1991 Strickland et al., , 1997 . The present review focuses on studies of black (African, African American, Bushmen) populations, in comparison with Caucasian and Asian populations.
There is little and conflicting information available on blacks (Africans, Bushmen, African Americans or Australian Aborigines). As can be seen from Table 2 , the incidence of PMs in Blacks has been estimated from 0 to 19 %. At least some of the conflicting results could be due to methodological differences, for example, polymorphism based on genotyping versus phenotyping, and different probe drugs. Although there is a good correspondence between probe drugs such as debrisoquine and sparteine, debrisoquine and metoprolol in Asian and Caucasian populations (Bertilsson, 1995 , Schmid et al., 1985 , this does not seem to be the case in Africans (see Table 3 ). Woolhouse (1986) reports that in a population of 233 Ghanaians, 5.6 % were classified as PM, using debrisoquine as the probe drug, similar to the 8.6 % PMs identified by Mbanefo et al. (1980) in Nigerians. In a separate study of oxidation of sparteine in 154 Ghanaians, not a single individual was classified as PM (in contrast to the control Caucasian group with 6 % . These results were confirmed in a crossover study of 141 Ghanaians, and a non-concordance between debrisoquine and sparteine was found . However, using debrisoquine as a probe drug, Iyun et al. (1988) found no PMs in either Nigerians and Ghanaians. Sommers et al. (1988 Sommers et al. ( , 1989a ) phenotyped a cohort of 96 Bushmen who migrated to South Africa in the early 1970s. With debrisoquine as the probe drug, 19 % were classified as PM, while only 4 % were identified using metoprolol. In a subsequent study, Sommers et al. (1989b Sommers et al. ( , 1991 found no PMs in a black South African cohort (while the village in the Venda was named, tribal origin was not specified), using sparteine as the probe drug ; but 4 and 7 % were identified by debrisoquine and metoprolol, respectively (Table 3) . Masimirembwa et al. (1996a) used debrisoquine and metoprolol to phenotype CYP2D6 activity in a Zimbabwean population. Phenotyping (n l 94) with debrisoquine revealed 2 PMs (2.1 %), while 5 (5.3 %) were Polymorphism of CYP2D6 in black populations classified PMs, using metoprolol. Only the 2 PMs who were identified with both probe drugs had corresponding PM genotypes.
All of the studies on the CYP2D6 polymorphism in African Americans have come from a single centre (St. Jude's Children's Research Hospital in Memphis, TN), using children as participants. Relling et al. (1991) , in a study of 468 unrelated white and 105 unrelated AfricanAmerican participants (mean age about 10 years), using dextromethorphan as an indicator for metabolic rate, found a significantly lower prevalence of PMs in black (1.9 %) versus white (7.7 %) participants. (See Table 3 for a summary of these and other data on Africans).
The two reported studies in black populations which used dextromethorphan as a probe drug identified 5 % (Burundians ; Nsabiyumva et al., 1991) and 1.9 % (AfricanAmerican children ; Relling et al., 1991) as PMs. It is possible that the difference in the reported frequency of PMs between the two African-American studies could be that the adults' phenotypic expression could have been affected by environmental influences.
CYP2D6 genotyping
Low metabolic activity of the CYP2D6 enzymes is inherited as an autosomal recessive gene (Bertilsson, 1995) . There are now more than 20 identified variant CYP2D6 alleles (Marez et al., 1997) , which contribute to the variation in CYP2D6 metabolism. The most common allelic variations associated with PM in Caucasians are CYP2D6*4 (75 %), *3 (5 %) and the gene deletion *5 (15 %) (Jurima-Romet et al., 1997) . Within this review, the nomenclature adopted by Daly et al. (1996) will be used. Table 4 shows the new nomenclature and the trivial names for the most common alleles associated with both poor and slow metabolism.
A further critical factor is that within EMs there is a range in MR of several hundred-fold. EMs can be categorized as ultra-rapid, intermediate, and slow metabolizers (Sachse et al., 1997) . This MR range appears to be due to various combinations of wild-type and mutant alleles, some of which are expressed as decreased enzyme activity (Daly et al., 1996) . Ultra-rapid EMs are due to an allele-duplication amplification (CYP2D6*2i2). Ultrarapid metabolizers have been observed more frequently in some subpopulations of Caucasians, for example, 7 % in Spanish and 10.4 % in Saudi Arabians, compared to 1 to 2 % in Swedish and Germans (Agu! ndez et al., 1995 ; McLellan et al., 1997) . Studies of Asians or Africans (Kalow and Bertilsson, 1994 ; Masimirembwa et al., 1993 Masimirembwa et al., , 1996a have also reported very low frequencies of gene duplication in Zimbabweans and Nigerians. However, Aklillu et al. (1996) reported that 29 % of Ethiopians, a non-Bantu African group, had gene duplications, the highest reported thus far.
It has been proposed that EM individuals homozygous for the wild-type allele have high metabolic rates, whereas those heterozygous for the wild-type and a non-inactivating mutant allele have an intermediate rate of metabolism. Those who are homozygous for these mutant alleles have the slowest metabolic rates within the EM classification (Roh et al., 1996) , although these findings have not always been replicated (Funck-Brentano et al., 1992) . Within Caucasian populations, alleles coding for slightly (CYP2D6*2) or moderately reduced (CYP2D6*9 or *10) metabolic activity occur at a frequency of 0.324, 0.18, and 0.15, respectively (Sachse et al., 1997) . When Bertilsson et al. (1992) compared Swedish Caucasians with Chinese, the MR of Chinese were shifted to the right, indicating a lower CYP2D6 activity. This phenomenon has also been demonstrated in Japanese and Koreans (Kalow, 1991 ; Kalow and Bertilsson, 1994 ; Llerena et al., 1996 ; Roh et al., 1996 ; Woolhouse, 1986a) . This is probably due to findings that Asians (Japanese, Chinese, Koreans) have a higher frequency of CYP2D6*10 allele (frequency l 0.23-0.7) compared to Caucasians (JurimaRomet et al., 1997 ; Roh et al., 1996 ; Sachse et al., 1997) . This diminished metabolic activity in Asians has been proposed to explain the increased incidence of adverse reactions to psychotropic medications when standard doses are given .
A unique CYP2D6 allele in Africans
In phenotyping studies, Zimbabweans (Bantu) who were EMs showed higher MRs than Caucasians in response to probe drugs (Masimirembwa et al., 1996a) . That, combined with the finding of non-concordance between probe drugs, prompted Masimirembwa to investigate the presence of a unique mutant allele. Further investigation of Zimbabwean EM phenotypes indicated that a mutant allele (CYP2D6*17) was associated with the diminished enzyme activity (Masimirembwa et al., 1996b) . The authors reported that among the Zimbabweans, 33\76 (43 %) were either heterozygous or homozygous for CYP2D6*17, while it was completely absent in Asians (Chinese) and Caucasians. Masimirembwa and Hasler (1997) have reported a CYP2D6*17 allele frequency of 20 % in the Venda population. Among Ethiopians (a non-Bantu African population), a CYP2D6*10 and CYP2D6*17 allele frequency of about 10 % was associated with diminished enzyme activity (Aklillu et al., 1996) . This is the same population which has been reported to have the highest frequency of gene duplication, indicating an Nagai et al. (1996) Polymorphism of CYP2D6 in black populations Mahgoub et al. (1977) * Indicates (subsets of) the same cohorts ; DM l dextromethorphan ; DQ l debrisoquine ; MT l metoprolol ; SP l sparteine (country of inhabitance). † Genotyping available ; † † 5-10 % depending upon criterion. enormous variability of metabolic rate among Ethiopians. The high incidence of CYP2D6*17 has also been determined in Ghanaians living in Canada (Droll et al., 1998) , African-American infants (S. Leeder and A. Gaedigk, personal communication) and in a small pilot study in healthy young adult African Americans (unpublished data). In a study from Relling and her colleagues, a subset of white and African-American participants previously phenotyped with dextromethorphan (Relling et al., 1991) were genotyped for CYP2D6 alleles. Evans concluded that the lower frequency of PMs in the African-American cohort, compared with the Caucasian cohort reported in the previous study, was due to a lower prevalence of the CYP2D6*4 mutant, which accounts for 75 % of Caucasian PMs. They found that the proportion of homozygous wild types was significantly higher in the black cohort compared with the white cohort (74.8 vs. 58.5 %) ; they also found a good correlation between the phenotype determined by dextromethorphan and the genotype. Masimirembwa et al. (1996b) reported that only 16 % of the Zimbabwean cohort were homozygous for the wild-type allele. This is in contrast to those of Evans et al. (1993) in an African-American population. Evans reported that 74.8 % were homozygous for the wild-type allele. Unfortunately, they did not report the distribution of MR for this group, so it is not possible from this study to compare the distribution of MRs in the white and the black cohorts for ultrarapid, normal and slow EMs, nor did they determine the presence of CYP2D6*17. The pre-Polymorphism of CYP2D6 in black populations ponderance of African-American participants who were homozygous for the wild-type allele reported in the Evans et al. (1993) study, would indicate that this cohort should have lower MRs when compared with the white cohort. This assumption, however, does not correspond to their previous study (Relling et al., 1991) , which reported that the MR actually tended to be higher in African-American participants than white participants, similar to that reported for Africans (Nigerians, Iyun et al., 1986 ; Zimbabweans, Masimirembwa et al., 1996a ; black South Africans, Sommers et al., 1989b ; Bushmen, Sommers et al., 1988 ; also see review by Kalow, 1991) .
The effect of migration on CYP2D6 polymorphism has been studied in Canadian-Indian populations. Nowak et al. (1997) phenotyped Canadian Native Americans, descendants of northern Asian populations, for CYP2D6-mediated dextromethorphan metabolism. Of the Canadian Native Americans, 1.1 % were PMs, statistically different from the Caucasian population (6.2 %) but not from Chinese (1.2 %). Interestingly, within the EMs, the frequency of the CYP2D6*10 allele, the most common mutant correlated with low MR in Asians, occurred no more frequently in the Canadian Native Americans than in Caucasians. Correspondingly, the mean MR for the Native Canadian-Indians was similar to Caucasians and lower than Chinese.
Incidence of PM in other migratory populations from northern Asia (Inuit and Greenlanders) has been reported to be intermediate between Caucasians and Asians (Table  2) . Although the mean of the EM metabolic ratio was not given in the report by Jurima-Romet et al. (1997) , it appears from visual inspection of the data that the mean MR of Inuit was more similar to Caucasian than Asian populations, and also similar to that of the other Canadian Native Indian population reported (Nowak et al., 1997) . In this study as well, the Inuit allele frequency for CYP2D6*10 was not different from Caucasians and was statistically lower than Asians (Jurima-Romet et al., 1997) . This would appear to indicate that the CYP2D6*10 mutation occurred in Asian populations after the migration of Native American populations.
The effects of migration are of particular interest to this institution since African Americans are its target population. Studies of African populations cited above indicate a lower metabolic activity among CYP2D6 EMs. In general, the African-American population would be expected to have a greater variance in CYP2D6 metabolism than Caucasian, Asian or African populations due, in part, to the wide range of metabolic activity among the dispersed African populations and the subsequent intermingling of these gene pools within the United States, not only between African populations but with Caucasian, Asian and Native American populations as well. Due to the expected heterogeneity of the African-American expression of CYP2D6 alleles and the unique CYP2D6*17 allele documented in African populations, a rigorous investigation of the potential differences in CYP2D6 drug metabolism between African American and Caucasian populations is necessary.
Clinical studies : CYP2D6-mediated response
Some generalizability of these phenotyping studies to the clinical situation can be assumed, since probe drugs such as debrisoquine, sparteine, and dextromethorphan have been shown to correlate well with the metabolism of other drugs mediated by CYP2D6, for example, tricyclic antidepressants (TCAs), classic neuroleptics and β-blockers such as metoprolol (Llerena et al., 1992 ; Sjo$ qvist, 1992 ; Strickland et al., 1991) . For drugs in which CYP2D6 plays a predominant role in metabolism, PMs will have the highest plasma concentrations and report the most severe adverse events (Meyer et al., 1990 ; Spina et al., 1997) . Studies in Caucasian EMs and PMs have uniformly demonstrated a 2-to 5-fold difference in the capacity to metabolize CYP2D6 substrates, such as antidepressants and neuroleptics (Dahl et al., 1991 ; Hamelin et al., 1996 ; Llerena et al., 1992 ; Spina et al., 1987 ; von Bahr et al., 1991) . However, very few comparative studies have been done on the variation in response to drug therapy in different populations (Jann et al., 1992) . The few studies of non-Caucasians have been carried out primarily with Asians and in these it appears that non-Westerners (Asians and Indians) may require lower doses of several classes of psychotropics (for example, classic neuroleptics and tricyclic antidepressants) that are metabolized by CYP2D6 than do Westerners (Lin, 1996 ; Lin et al., 1986 Lin et al., , 1991 Lin et al., , 1995 Turner and Cooley-Quille, 1996) . Masimirembwa et al. (1996b Masimirembwa et al. ( , 1997 concluded their results by suggesting that it may be desirable to reduce doses in black populations as in Asian populations. The implications for African-American populations are similar (Edeki, 1996 ; Lawson, 1996 ; Strickland et al., 1991 Strickland et al., , 1997 . Very little information is available on drugs metabolized by CYP2D6 in African Americans, as reviewed below. Clearly, more studies are needed.
Neuroleptics
Plasma levels of several neuroleptics are increased by PM status (Dahl et al., 1991 ; Linnet and Woborg, 1996 ; Meyer et al., 1990 ; Sjo$ qvist, 1992 ; von Bahr et al., 1991) , as well as adverse events (Spina et al., 1992) . Reviews of the literature (Lin, et al., 1986 ; Turner and Cooley-Quille, 1996) , reported racial\ethnic differences in patients taking neuroleptics and tricyclic antidepressants : Asians need lower doses to achieve the same therapeutic response (Lin et al., 1986) . Asians were more likely to report more sideeffects, including extrapyramidal side-effects (EPS) than either African Americans or Caucasians (Lin et al., 1986) , while African Americans experience more side-effects than Caucasians (Lawson, unpublished ; Sellwood and Tarrier, 1994) . Jann et al. (1992) , in a rare comparison of four ethnic groups, compared haloperidol and reduced haloperidol plasma levels in Chinese (n l 156), Caucasians (n l 37) and African-Americans (n l 23). The Chinese cohort had significantly higher plasma levels of haloperidol compared with either the Caucasians or the African Americans. African Americans had higher plasma levels of the metabolite than the other groups. These results are intriguing, since the African-American cohort might have been expected to resemble the Asian cohort more closely regarding metabolic rate. While the plasma level of the parent compound of the African-American cohort was similar to that of Caucasians, the metabolite (RHAL) level was higher than all the other groups. Note, however, that except for the Chinese cohort, the number of the other cohorts was very small. Further studies are warranted in African Americans with identified metabolic status.
Lawson (unpublished) presented data which suggest ethnic\racial short-term dynamic differences in response to antipsychotic treatment. A retrospective data analysis was conducted of patients treated with olanzapine or haloperidol during the acute phase (6 wk) of a longer study (Lilly, data available from Lilly on request). Within the haloperidol-treated cohorts during the acute treatment phase of the protocol, Asians tended to show the highest incidence of EPS, followed by African Americans, who were higher than Caucasians. All three ethnic cohorts treated with olanzapine showed a decrease in the emergence of EPS compared with haloperidol, and there were no racial\ethnic differences between the groups. The results are provocative, since olanzapine may be metabolized primarily by CYP1A2. Data from in vitro studies, and in vivo clinical pharmacology studies in EMs and PMs indicate a relatively minor role of CYP2D6 enzymes in the metabolism of olanzapine (Ring et al., 1996 , Lilly, data available from Lilly on request).
It would be an attractive hypothesis to propose that the higher MR within EMs observed in Asians, African and African-American populations might be the basis for an increased risk of EPS observed in those populations, associated with classical neuroleptic treatment. However, it should be noted that Arthur et al. (1995) found no correlation between the development of tardive dyskinesia (a long-term consequence compared with other EPs) and PM status.
Antidepressants
Poor metabolizer status is related to higher plasma levels and increased adverse events with many tricyclic antidepressants (Sjo$ qvist, 1992 ; Spina et al., 1997) and some serotonin-specific re-uptake inhibitors (Hamelin et al., 1996) . Higher plasma levels of TCAs could account for the reports of faster and better response, and the increase of adverse events of African Americans to TCAs (Edeki, 1996 ; Lawson, 1996 ; Strickland et al., 1991 Strickland et al., , 1997 . There is some evidence to support this. In a retrospective study of patients who overdosed with amitriptyline, plasma levels were 30 % higher in black patients, although the magnitude of the overdose was similar in black and white patients. An examination of the individual patient data indicated that the higher mean levels in the AfricanAmerican (female) cohort could be accounted for by 2 patients, but the groups were too small to draw conclusions. It should be noted, however, that all 6 black patients were women, while 5 of the 13 white patients were male (Rudorfer and Robins, 1982) . Ziegler and Biggs (1977) , in a study of white and African-American depressed patients, found a 50 % higher steady-state nortriptyline plasma level in the black cohort compared with the white patients. Unfortunately, neither information regarding individual data nor variability was provided, so it is not possible to determine if the increased plasma levels reported for the group were due to a general shift for the black cohort, or a few extreme outliers.
In an early clinical study (Raskin and Crook, 1975) , black and white depressed inpatients were compared with regard to clinical response to either chlorpromazine or imipramine. The authors concluded that black patients showed a greater clinical improvement than whites, especially during the first 3 wk of treatment. Interpretation of the clinical response reported here is difficult, however, because the diagnosis of the cohort is not clear. Unfortunately, adverse events and plasma levels were not reported, although the number of patients terminating treatment early because of side-effects was about the same in the black and white cohorts. Another early study by Overall et al. (1969) also reported that a cohort of black patients responded better than white patients to a number of psychotropic drugs, including tricyclics and neuroleptics. Again, it is difficult to interpret these results because the diagnoses of the cohorts was not clear. Henry et al. (1971) reported that minority (predominantly African-American) psychiatry outpatients Polymorphism of CYP2D6 in black populations responded better to tricyclic antidepressants than did the Caucasian patients. In a retrospective chart analysis, Livingston et al. (1983) indicated that reports of delirium were more frequent in African Americans being treated with TCAs than Caucasians. Strickland et al. (1997) report a study in depressed Africans in Tanzania being treated by clomipramine. They responded in much lower doses (125 mg) than normally recommended, and reported notable side-effects.
The clinical studies reporting better clinical response are suggestive of higher plasma levels of tricyclic antidepressants, but it still remains to be demonstrated in well-controlled clinical pharmacology trials with Africans and African Americans. Further phenotyping and genotyping studies are also necessary to quantify polymorphism of CYP2D6 and identify the genetic basis in these populations. The limited data available on pharmacokinetics parameters in Africans and African Americans clearly indicate the necessity of studies determining dose, efficacy and safety of drugs being widely used within these populations.
